Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Other Non Operating Income (2017 - 2025)

Autolus Therapeutics' Other Non Operating Income history spans 6 years, with the latest figure at $363000.0 for Q4 2025.

  • For Q4 2025, Other Non Operating Income rose 131.27% year-over-year to $363000.0; the TTM value through Dec 2025 reached $787000.0, up 106.48%, while the annual FY2025 figure was $2.2 million, 316.3% up from the prior year.
  • Other Non Operating Income reached $363000.0 in Q4 2025 per AUTL's latest filing, up from -$911000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $6.3 million in Q4 2022 to a low of -$11.9 million in Q3 2024.
  • Average Other Non Operating Income over 4 years is -$453875.0, with a median of $249000.0 recorded in 2025.
  • Peak YoY movement for Other Non Operating Income: plummeted 599.06% in 2024, then skyrocketed 500.0% in 2025.
  • A 4-year view of Other Non Operating Income shows it stood at $6.3 million in 2022, then plummeted by 60.16% to $2.5 million in 2023, then crashed by 146.61% to -$1.2 million in 2024, then surged by 131.27% to $363000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Other Non Operating Income are $363000.0 (Q4 2025), -$911000.0 (Q3 2025), and $135000.0 (Q2 2025).